chrisvoncsefalvay/vaers-outcomes huggingface dataset:
This case was reported by a consumer via call center representative and described the occurrence of influenza-like symptoms in a 56-year-old female patient who received SHINGRIX for prophylaxis. Co-suspect products included SHINGRIX for prophylaxis. On 27th April 2018, the patient received the 1st dose of SHINGRIX (intramuscular) .5 ml. On an unknown date, the patient received the 2nd dose of SHINGRIX. On 27th April 2018, less than a day after receiving SHINGRIX and not applicable after receiving SHINGRIX, the patient experienced influenza-like symptoms, general body pain and fever. On an unknown date, the patient experienced product supply issue. On 30th April 2018, the outcome of the influenza-like symptoms, general body pain and fever were recovered/resolved. On an unknown date, the outcome of the product supply issue was unknown. It was unknown if the reporter considered the influenza-like symptoms, general body pain and fever to be related to SHINGRIX. Additional details were reported as follows: The patient received SHINGRIX vaccine in left arm. In the evening the patient developed flu like symptoms, including body aches and fever. The reporter reported that the patient was late to receive second dose of the SHINGRIX vaccine, as the last day for her to have received it in order to be within the six month time frame was 27th October 2018. The patient was already about 10 days past for six month mark. The patient was trying for weeks now to find the second vaccine. The reporter gave permission for her physician to be contacted.
Some enlargement of thyroid; 3 weeks ago she started to have difficulty sleeping; 5 weeks ago She started to develop  diaphoretic episodes that her clothes were soaked with sweat; This spontaneous case was reported by a consumer and describes the occurrence of HYPERHIDROSIS (5 weeks ago She started to develop  diaphoretic episodes that her clothes were soaked with sweat), INSOMNIA (3 weeks ago she started to have difficulty sleeping) and GOITRE (Some enlargement of thyroid) in a 73-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 006B21A and 040A21A) for COVID-19 vaccination.     No medical history was provided by the reporter.  Concomitant products included Metoprolol; Lisinopril; Coumadin; Rosuvastatin; Tylenol; Fish Oil; Melatonin for an unknown indication.   On 12-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 09-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 27-Sep-2021,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced HYPERHIDROSIS (5 weeks ago She started to develop  diaphoretic episodes that her clothes were soaked with sweat). On 04-Oct-2021, the patient experienced INSOMNIA (3 weeks ago she started to have difficulty sleeping). On an unknown date, the patient experienced GOITRE (Some enlargement of thyroid). At the time of the report, HYPERHIDROSIS (5 weeks ago She started to develop  diaphoretic episodes that her clothes were soaked with sweat), INSOMNIA (3 weeks ago she started to have difficulty sleeping) and GOITRE (Some enlargement of thyroid) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 27-Sep-2021, Heart rate: rapid pulse (abnormal) Rapid pulse. On an unknown date, Blood thyroid stimulating hormone: normal (normal) Normal. On an unknown date, Thyroxine: normal (normal) Normal.   Treatment information was not provided.
pt recv vax & devel weakness, cold sweats, elevated temp alternating w/low grade temp, nausea, heightened sensation of smell & abd soreness on 11OCT96 p/vax 30SEP96;pt went to MD 15OCT96 & was dx w/enlarged liver;
Information has been received from a 75 year old female patient with blood cholesterol abnormal who in April or May 2007 was vaccinated with ZOSTAVAX. On 26-AUG-2008, the patient developed shingles on her upper right corner of her face. Routine lab tests were done, but results not reported. The pain and rash was healed about 10 days after her diagnoses. No further information was provided.
I had the normal painful arm for a couple days after the vaccine.  Everything else felt great. However, speaking to my co workers, their painful arm went away after 2 or 3 days.  Mine still hurts over a week afterwards.  I got my vaccine on a Saturday. Wednesday night, I started feeling pain in my armpit.  It has continued and not stopped.  Feeling around, it feels like my lymph nodes are swollen under my armpit.   Saturday night (a week now after the vaccine), the vaccination site on my arm started itching unbelievably. Nothing would help it. It subsided by Sunday morning but now I noticed the skin around my vaccination site is pink/red.  Not infected looking, just like the coloring of the skin is different, almost like  a sunburn.  Again, still have painful, swollen lymph nodes under my arm and my armpit hurts when I move my arm.
About 4 days post vax, the patient attempted to dance and her legs gave out. The next morning the patient was unable to get out of bed. The patient complained of severe joint pain with inflammation. Saw Dr and was referred to a specialist. Diagnosed with rheumatoid arthritis. Patient states she has eye problems also.
Swollen left lymph node in under arm occurred day of vaccination and lasted for 4-5 days.   Diagnosis of papillary thyroid carcinoma may 26, 2021 in right thyroid lobe
Patient said red ring formed about 3-4 inches out, fever of 105, went to doctor and doctor said was infected, patient remembers vaccinator using gloves and swabbing, (suspect pneumo shot).
This is spontaneous case, initially received on 24-Jan-2018, was reported by a other health professional and concerns a 30-year-old, adult female patient. The patient's medical history and concomitant medications were not reported. On 24-Jan-2018, the patient was administered with half dose of AFLURIA QUADRIVALENT (dose: 0.25 ml, route of administration: intramuscular, anatomical location: deltoid, batch number: XF35109, expiry date: 30-Jun-2018) (explicitly considered as incomplete dose administered), as rest of the vaccine leaked down her arm (explicitly considered as exposure via skin contact). It was reported that, no adverse events were noted. The reporter assessed the case as non-serious.
6 cm x 8 cm red, warm, indurated punctate site; (R) arm deltoid. (+) tender to touch. C/O arm with pain (not severe). Able to move arm. Vaccine given 11/30/11; S/S same P.M. Tx = MOTRIN 800 mg Q6 - 8 hours; Rtn to PCP with increased pain > 48 hours; LROM.
I had cryptogenic stroke on Sept 5th and then again 10days later. The stroke resulted in my left side being weak/paralyzed.  after extensive testing over the course of 1 month, other factors such as BP and cholesterol were ruled out and after cardiolipin and beta 2 glycoprotein anti-body tests, it was determined that I have Primary Anti-Phospholipid syndrome.  There is no family history of this and no other cause determined to lead up to this diagnosis.
she has a friend with irisitis since getting a dose of the vaccine; inflammation of the eye; This is a spontaneous report from a contactable physician. A male patient of an unspecified age received BNT162B2 (BNT162B2, PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection, Batch/Lot number was not reported) via an unspecified route of administration on an unspecified date as dose number unknown, single for COVID-19 immunization. The patient medical history and concomitant medications were not reported. The patient experienced she has a friend with irisitis since getting a dose of the vaccine and inflammation of the eye on an unspecified date. The outcome of the events was unknown.  The lot number for the vaccine, [BNT162B2], was not provided and will be requested during follow up.
My arm swelled up about 30 minutes after the injection near my shoulder. I started feeling pain in my forearm and the facility nurse gave me an ice pack. I stayed an hour after the shot and the nurse said I should be fine, so I went home. Around 10 pm I started having a really bad reaction, worse than normal flu symptoms. A fever of 102 and body chills that lasted for about an hour. Heart rate also consistently stayed above 130 bpm. I drank a lot of water and took an Advil. I then was advised to take a warm shower, and this helped bring my fever to a 99. After the shower, I became really nauseous and started throwing up. I was debating going to the ER. I also drank chicken broth and a lot of water and did not go to sleep until 4 am.  The next two days I had a low fever and bad muscle aches throughout my body, the flu symptoms ended in 4 days.
Very swollen at injection site, red and hot to touch. Running a fever of 102. Lethargic and no appetite. Leg hurts to walk on and knee is swelling as well.
Asthma attack; Discomfort itching of throat and sight; Discomfort itching of throat and sight; This is a spontaneous report received from a contactable reporter(s) (Other HCP). The reporter is the patient. A 51-year-old female patient (not pregnant) received bnt162b2 (BNT162B2), administered in arm left, administration date 19Jul2021 13:45 (Batch/Lot number: unknown) at the age of 51 years as dose 1, single for covid-19 immunisation. Relevant medical history included: "Severe asthma" (unspecified if ongoing). Concomitant medication(s) included: DUPIXENT; TRELEGY; ADVAIR. Past drug history included: Iodine, reaction(s): "Iodine allergy"; Ceclor, reaction(s): "Ceclor allergy"; Niacin, reaction(s): "Niacin allergy". The following information was reported: ASTHMA (non-serious) with onset 20Jul2021 06:00, outcome "unknown", described as "Asthma attack"; OROPHARYNGEAL DISCOMFORT (non-serious), THROAT IRRITATION (non-serious) all with onset 20Jul2021 06:00, outcome "unknown" and all described as "Discomfort itching of throat and sight". The events "asthma attack", "discomfort itching of throat and sight" and "discomfort itching of throat and sight" were evaluated at the physician office visit. Therapeutic measures were taken as a result of asthma, oropharyngeal discomfort, throat irritation.  Additional information: Facility type vaccine was pharmacy or drug store. No other vaccine in four weeks. No covid prior vaccination. No covid tested post vaccination. Known allergies for iodine, ceclor, niacin. Other medical history was severe asthma. Other medications in two weeks were Dupixent, Trelegy, Advair. Adverse events were asthma attack, discomfort itching of throat and sight. Adverse events resulted in doctor or other healthcare professional office/clinic visit. Adverse event treatment was Bendryl, rescue inhalation.  Follow-up attempts completed. No further information is expected.
This spontaneous report as received from a medical assistant refers to a 9.5 month old patient of unknown gender. The patient's medical history, concurrent conditions and concomitant medications were not reported. On 23-JUN-2015, the patient was in the office in order to get the third dose of ROTATEQ, oral, (dose, lot number and expiration date were not reported). No adverse effects were reported. Additional information has been requested.
The night (9:00 pm) the vaccine was administered the baby woke up vomiting, rectal temperature of 104, chills and heavy breathing. He was not previously sick. Also, the following morning when the fever was gone the baby showed no continued signs of being sick.
This spontaneous report as received from a medical assistant refers to a multiple unspecified patients of unknown age and gender. The patients' concurrent conditions, medical history and concomitant therapies were not reported. On an unknown date, the patient received improperly stored (temperature: 34 degrees Fahrenheit and 51 degrees Fahrenheit for 14 hours; no previous excursion was reported) doses of oral ROTATEQ lot # L029618 and expiration date: 20-MAY-2017 (dose was not reported, route of administration defaulted to oral). No adverse effects were reported. This is one of several reports received from the same reporter. Additional information has been requested.
Pt vaccinated with Recombivax developed chills & fever, had sore throat, general malaise, profuse sweating, severe headache & joint pain later developed a rash.
Fever, severe chest pain/throbbing of the chest area, heart arrhythmia. Fever began Thursday 5/13, with the chest pain, throbbing and arrhythmia following early morning on Friday 5/14. 911 was called Saturday afternoon, 5/15. Was taken by ambulance to hospital, after which several tests were administered including a chest X-ray, blood tests, heart stress test, as well as an ultrasound of the heart/chest area. Stayed in hospital for from Saturday 5/15 to Monday, 5/17. Was released 5/17 at approximately 6:00 pm.  Further treatments included prescriptions of Amoxicillin, Atenolol, and Ibuprofen.
JNASEEN COVID-19 VACCINE EUA Fever, Body aches, headache, chills, vomiting for 2 days
pt recvd vax; lab tests done & revealed neg anti-HBs; when 2nd dose admin, pt was feeling "poorly" to the vax & complaining of a sore throat;
Pt received vaccines (#13) at approx 3P. At approx 7:10 p ate lunch-Then few minutes later Hives noticed on (L) arm, disoriented, dizziness, and pale skin color noted by supv.,-transported to ED-Temp Normal, B/P increased, Benadryl and steroid injections on the way to ED-became short of breath and knees felt stiff Approx 20 min. after injections, pt felt better-on a Prednisone dose pkg now.
1 day p/vax pt devel redness, sl swelling & warmth @ each inj site;the affected areas measured 9cm in diameter on lt deltoid & 8cm in diameter on the rt deltoid;pt was seen by MD 2 days post vax;MD dx bilat cellulitis & rx keflex,DPH, advil
Irritation at injection site; Redness at injection site; Warm to touch at injection site; A spontaneous report was received from a consumer concerning a 40-years-old female patient who received Moderna's COVID-19 vaccine (mRNA-1273) and experienced events irritation at injection site, redness at injection site, warm to touch at injection site.  The patient's medical history was not provided. Concomitant medications reported were birth control (unspecified) used for unknown indication.  On 30 Jan 2021, prior to the onset of the events the patient received first of two planned doses of mRNA-1273 (lot/batch: 012M0A) via unknown route for prophylaxis of COVID-19 infection.  On 6 Feb 2021, after receiving the first dose of mRNA-1273, the patient experienced the event(s) irritation at injection site, redness at injection site, warm to touch at injection site.  Treatment details included methylprednisolone, diphenhydramine.  Action taken with mRNA-1273 in response to the events was unknown.   The outcome of event(s), irritation at injection site, redness at injection site, warm to touch at injection site was unknown.; Sender's Comments: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.
Injection site wam to touch; Redness, swelling, itchiness at the injection site; Redness, swelling, itchiness at the injection site; Redness, swelling, itchiness at the injection site; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE WARMTH (Injection site wam to touch), VACCINATION SITE PRURITUS (Redness, swelling, itchiness at the injection site), VACCINATION SITE SWELLING (Redness, swelling, itchiness at the injection site) and VACCINATION SITE ERYTHEMA (Redness, swelling, itchiness at the injection site) in a 68-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 042120A) for COVID-19 vaccination.     No Medical History information was reported.    On 15-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 22-Jan-2021, the patient experienced VACCINATION SITE WARMTH (Injection site wam to touch), VACCINATION SITE PRURITUS (Redness, swelling, itchiness at the injection site), VACCINATION SITE SWELLING (Redness, swelling, itchiness at the injection site) and VACCINATION SITE ERYTHEMA (Redness, swelling, itchiness at the injection site). At the time of the report, VACCINATION SITE WARMTH (Injection site wam to touch), VACCINATION SITE PRURITUS (Redness, swelling, itchiness at the injection site), VACCINATION SITE SWELLING (Redness, swelling, itchiness at the injection site) and VACCINATION SITE ERYTHEMA (Redness, swelling, itchiness at the injection site) had not resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant product use was not provided. Treatment information was not provided.   It was reported that patient received second dose of vaccine.   Most recent FOLLOW-UP information incorporated above includes: On 08-Jun-2021: Follow up received on 08-JUN-2021 contains added vaccine information.
hands got itchy, both the outside and the inside, in between fingers and  palm; This is a spontaneous report from a contactable consumer, the patient. A 67-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 28Mar2021 at 13:15 (at the age of 67-years-old) as a single dose for COVID-19 immunisation. Medical history included Irritable Bowel Syndrome (IBS) and hay fever. The patient was allergic to penicillin. Concomitant medications included lansoprazole (MANUFACTURER UNKNOWN), citalopram (MANUFACTURER UNKNOWN) and fexofenadine (MANUFACTURER UNKNOWN), all taken for unspecified indications from unknown dates. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on an unknown date as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 01Apr2021, 4 days after the second vaccination, the patient experienced itchy hands. She had a penicillin allergy and this event was causing much more severe itching. This was just in her hands, both the outside and the inside, in between fingers and palm itched the most. The itchiness was coming and going but was present at the time of this report. Therapeutic measures were not taken as a result of the events. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. The clinical outcome of the event itchy hands both the outside and the inside, in between fingers and palm was not resolved at the time of this report.  No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Moderna COVID-19 Vaccine EUA.  Became very sick Friday with flu like symptoms- fever, shaking, chills, nausea, body aches, headache, stomach pain, injection site pain and redness. Saturday and Sunday- headache, body aches, stomach pain, injection site redness, pain, raised welts and itching. Developed pepper like rash on left upper back and left breast with redness coming and going all over body.  Visited my PCP today- currently taking Benedryl.
Fever over 101 degrees for 5 days and lost the toileting ability.  Has not regained the toileting ability
received vaccine from vaccine that underwent a temperature excursion in the Freezer; No adverse event; doses administered after excursion; This spontaneous case was reported by a pharmacist and describes the occurrence of POOR QUALITY PRODUCT ADMINISTERED (doses administered after excursion), PRODUCT TEMPERATURE EXCURSION ISSUE (received vaccine from vaccine that underwent a temperature excursion in the Freezer) and NO ADVERSE EVENT (No adverse event) in a 71-year-old female patient who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. AS7147B) for COVID-19 prophylaxis.     No Medical History information was reported.    On 17-Oct-2022, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On 17-Oct-2022, the patient experienced POOR QUALITY PRODUCT ADMINISTERED (doses administered after excursion). On an unknown date, the patient experienced PRODUCT TEMPERATURE EXCURSION ISSUE (received vaccine from vaccine that underwent a temperature excursion in the Freezer) and NO ADVERSE EVENT (No adverse event). At the time of the report, POOR QUALITY PRODUCT ADMINISTERED (doses administered after excursion), PRODUCT TEMPERATURE EXCURSION ISSUE (received vaccine from vaccine that underwent a temperature excursion in the Freezer) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessments were provided for POOR QUALITY PRODUCT ADMINISTERED (doses administered after excursion) and PRODUCT TEMPERATURE EXCURSION ISSUE (received vaccine from vaccine that underwent a temperature excursion in the Freezer).    No concomitant medications were reported. Reportedly, pharmacist called to discuss a temperature excursion that occurred several days ago in the freezer. The excursion was found out in an audit and all the vaccines were viable. No treatment medications were reported.
First dose Pfizer given at 0945,  At 1000, starting c/o itching and rash on forearms.  25mg PO Benadryl given.  Continued to be observed. At 1020 stated felt better.
PATIENT WAS CALLED ON PHONE TO DISCUSS HER SECOND DOSE OF VACCINE. IT WAS DISCOVERED THAT SHE "ENDED UP IN THE HOSPITAL 2 DAYS AFTER SHE RECEIVED HER FIRST DOSE OF PFIZER VACCINE ON 3/16/2021. NO DETAILS WERE GIVEN EXCEPT FOR SHE BELIEVES THE SEVERE REACTION COULD BE RELATED TO THE FACT THAT SHE HAS STAGE 4 LUNG CANCER. SHE STATES SHE IS "FINE" AT THE TIME OF CALL.  SHE WILL CONSULT WITH HER PROVIDER BEFORE GOING FORTH WITH HER SECOND DOSE.
Lump in arm mild soreness less than 24 hours . Tired and mild diarrhea for less than 24 hours .